Safety and efficacy of an initial regimen of atazanavir + ritonavir + the abacavir/lamivudine [Epzicom] fixed dose combination tablet (ABC/3TC FDC) for 36 weeks followed by simplification to atazanavir with ABC/3TC FDC or maintenance of the initial regimen for additional 48 weeks in antiretroviral therapy naive HIV-1 infected HLA [human leukocyte antigen]-B*5701 negative subjects
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jun 2009
At a glance
- Drugs Atazanavir (Primary) ; Lamivudine/abacavir (Primary) ; Ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 10 Jun 2009 Status changed from not stated to active, no longer recruiting.
- 03 Apr 2007 New trial record.